Skip to main content
Log in

Mechanism based medicine in infancy: complex interplay between developmental pharmacology and pharmacogenetics

  • Commentary
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Introduction of the available knowledge on pharmacogenetics very likely is one of the tools to close the gap between ‘population’ focused evidence based and ‘individual’ mechanism based medicine. However, besides pharmacogenetics, other covariates like age, renal function and/or co-medication should also be considered simultaneously when aiming for a ‘tailored’ pharmacotherapy. To illustrate this, we further extended the tramadol example used by Wilffert et al. to illustrate the complex interplay between developmental pharmacology and pharmacogenetics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Wilffert B, Swen J, Mulder H, et al. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Pharm World Sci. 2010. doi:10.1007s/s11096-010-9446-1.

  2. Allegaert K, van Schaik RH, Vermeersch S, et al. Postmenstrual age and CYP2D6 polymorphisms determine tramadol O-demethylation in critically ill neonates and infants. Pediatr Res. 2008;63:674–9.

    Article  PubMed  CAS  Google Scholar 

  3. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr Anaesth 2011;21(3):266–73. doi: 10.1111/j.1460.9592.2010.03389.x.

  4. Stamer UM, Stuber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anasth Analg. 2008;107:926–9.

    Article  Google Scholar 

  5. Nielsen AG, Pedersen RS, Noehr-Jensen L, Damkier P, Brosen K. Two seperate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol’s O-demethylation via CYP2D6. Eur J Clin Pharmacol. 2010;66:655–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The clinical research of Karel Allegaert is supported by the Fund for Scientific Research, Flanders (Belgium) (F.W.O. Vlaanderen) by a Fundamental Clinical Investigatorship (1800209 N).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karel Allegaert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allegaert, K. Mechanism based medicine in infancy: complex interplay between developmental pharmacology and pharmacogenetics. Int J Clin Pharm 33, 473–474 (2011). https://doi.org/10.1007/s11096-011-9504-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-011-9504-3

Keywords

Navigation